Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering June 11, 2019 • 5:30 AM EDT
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting June 3, 2019 • 8:45 AM EDT
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results May 15, 2019 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering May 8, 2019 • 8:12 AM EDT
DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference May 6, 2019 • 5:30 AM EDT